San Diego startup Gallant has secured $18 million in funding to develop the first FDA-approved ready-to-use stem cell therapy for veterinary medicine.
The therapy aims to address conditions in pets like Feline Chronic Gingivostomatitis (FCGS) and arthritis, with promising early results showing improvements in pain and mobility.
Gallant's approach differentiates itself by utilizing ready-to-use cells from donor animals, potentially simplifying the treatment process compared to traditional stem cell therapies.
Investors, including Digitalis Ventures and NovaQuest Capital Management, are optimistic about Gallant's potential, recognizing its novel approach and convenience.